Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Sees Large Increase in Short Interest

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) was the target of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 2,710,000 shares, an increase of 1,180.7% from the January 15th total of 211,600 shares. Based on an average daily trading volume, of 17,180,000 shares, the short-interest ratio is currently 0.2 days. Currently, 25.5% of the shares of the company are sold short.

Hepion Pharmaceuticals Price Performance

NASDAQ:HEPA traded down $0.01 during trading hours on Friday, reaching $0.19. 4,245,096 shares of the company were exchanged, compared to its average volume of 39,302,922. The company has a market capitalization of $1.32 million, a P/E ratio of -0.04 and a beta of 1.65. The business has a 50 day moving average of $0.41 and a 200 day moving average of $0.59. Hepion Pharmaceuticals has a 1-year low of $0.12 and a 1-year high of $3.49.

Hedge Funds Weigh In On Hepion Pharmaceuticals

A hedge fund recently bought a new stake in Hepion Pharmaceuticals stock. Anson Funds Management LP purchased a new position in shares of Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 231,849 shares of the company’s stock, valued at approximately $155,000. Anson Funds Management LP owned 3.33% of Hepion Pharmaceuticals as of its most recent filing with the SEC. Hedge funds and other institutional investors own 17.24% of the company’s stock.

About Hepion Pharmaceuticals

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.